Refractory Hematologic Malignancies or Solid Tumors research hub

Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

This clinical trial is testing a new drug called elraglusib in adults with blood cancers or solid tumours. It looks at whether elraglusib, taken alone or alongside standard chemotherapy medicines, is safe and can help control cancer that has not responded to other treatments.